Most people think that vaccines provide them with an impenetrable shield against bacterial and viral infections. It’s probably time to rethink that paradigm, shifting the focus from “prophylactic” vaccines that produce antibody to protect against infection – to “therapeutic prophylactic” … Continue reading →

Of bugs and men. Human beings, unlike their experimental counterparts (mice), do not live in a controlled environment. The immune repertoire of a human is shaped by exposures to infections and vaccinations from birth until death. While it is not … Continue reading →

The discovery of natural regulatory T cell epitopes in the sequence of therapeutic mAbs represents a paradigm shift for protein therapeutics, allergy, autoimmunity and transplantation. These natural Treg epitopes (also known as Tregitopes) are promiscuous MHC Class II T cell … Continue reading →

If you want to hear about Tregitope join us (for free) in Boston on May 16th, at the Westin Copley. Email Shannon Pelletier spelletier@epivax.com and we’ll reserve your seat. The discovery of natural regulatory T cell epitopes in the sequence … Continue reading →

Antibodies are shape shifters. What is shape shifting? It’s a common theme in fairytales and involves the transformation of an animal or person into something else, whether permanently or transiently. For example, a woman can become a bear or a … Continue reading →

In 2008, based on a recommendation by the 9/11 Commission, a bipartisan Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism was created to: (1) assess the nation’s current activities and capabilities to prevent WMD proliferation and … Continue reading →

The discovery of natural regulatory T cell epitopes (Tregitopes [i]) in the sequence of therapeutic mAbs represents a paradigm shift for protein therapeutics, allergy, autoimmunity and transplantation. These natural Treg epitopes (also known as Tregitopes) are promiscuous MHC Class II … Continue reading →

F is for Flu (and other pandemic and bioterror preparedness) 14 months have passed since the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism (WMD commission) predicted that a terrorist event involving a biologic weapon would … Continue reading →

You won’t see EpiVax in Prague this February. And you won’t hear about EpiVax’ new tolerizing technology at the PEGS conference in Boston unless you come a day early to the Tregitope meeting. And we won’t be at IBC in … Continue reading →

One of the great surprises of the biologics revolution has been the discovery that recombinant human proteins, including fully human monoclonals such as Humira, can cause immune responses when administered to immune-competent subjects. An even greater surprise, to some, is … Continue reading →